FDA expands indication for Medtronic's stent graft

Editorial Staff | | Cardiovascular Business | Vascular & Endovascular

The FDA has approved Medtronic's Valiant Captivia stent graft system for the endovascular repair of isolated lesions (excluding dissections) of the descending segment of the thoracic aorta. This expanded indication includes the treatment of transections, or blunt traumatic aortic injuries, according to the company. 

The Valiant stent graft, a tubular medical device consisting of a woven fabric sewn onto a flexible wire-mesh frame, can now be used in U.S. clinical practice to stabilize bleeding from descending thoracic aortic transections as an alternative to invasive surgery. Previously approved by the FDA for the endovascular repair of aneurysms and penetrating ulcers of the descending thoracic aorta, the Valiant Captivia stent graft system has been available since May in the U.S.

The device is implanted in a minimally invasive procedure that uses a catheter inserted into the femoral artery, which requires only a small incision to access the aorta as opposed to larger incisions required for open surgery. Compressed inside the delivery system, the device passes through several arteries in the abdomen and up the aorta to the location of the damaged area. By turning a mechanism on the handle of the delivery system, Medtronic said, the stent graft opens from top to bottom, creating a new path for blood flow.

The new indication for thoracic aortic transections followed the FDA’s review of the results of the RESCUE trial, which enrolled 50 patients across 20 U.S. and Canadian sites. Six-month results from the RESCUE trial will be presented at the VEITHsymposium in New York City, Nov. 14-18.

Editorial Staff

Related Content

IVUS-guided PCI reduces risks in patients with diabetes
LAAC with Watchman FLX reduces bleeding risks after AFib ablation
Bioresorbable BTK stent superior to ballon angioplasty at 2 years
Shockwave Medical’s IVL technology delivers more positive outcomes for PAD patients
Standing desks fail to lower blood pressure or minimize heart risks—they may even do damage
IVL vs. RA for chronic total occlusion PCI: Key data cardiologists should know

Around the web

Health Imaging
Use of AI opportunistic screening in CT for cardiovascular disease

Ron Blankstein, MD, professor of radiology, Harvard Medical School, explains the use of artificial intelligence to detect heart disease in non-cardiac CT exams.

Health Imaging
New imaging protocols proposed to curb rise of cardiovascular infections

Eleven medical societies have signed on to a consensus statement aimed at standardizing imaging for suspected cardiovascular infections.

Radiology Business
What does radiology have to do with climate change?

Kate Hanneman, MD, explains why many vendors and hospitals want to lower radiology's impact on the environment. "Taking steps to reduce the carbon footprint in healthcare isn’t just an opportunity," she said. "It’s also a responsibility."